Irritable Bowel Syndrome (IBS) Treatment Market Expansion Continues, with Forecast Valuation of $4.9 Billion by 2029

Use code ONLINE20 to get 20% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Irritable Bowel Syndrome (IBS) Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
The market addressing irritable bowel syndrome (IBS) treatments has experienced robust expansion lately; it is projected to move from its 2024 valuation of $2.79 billion to $3.06 billion in 2025, reflecting a compound annual growth rate (CAGR) of 9.8%, with historical growth being fueled by factors such as the escalating incidence of IBS, greater patient understanding, lifestyle and stress influences, supportive patient groups and advocacy, alongside favorable healthcare reimbursement frameworks.

Irritable Bowel Syndrome (IBS) Treatment Market Size Forecast: What's the Projected Valuation by 2029?
The global market value for irritable bowel syndrome (IBS) therapeutics is projected for substantial expansion in the upcoming years, reaching an estimated $4.9 billion by 2029, propelled by a compound annual growth rate (CAGR) of 12.5%.This accelerated expansion throughout the projection timeframe is largely fueled by the increasing adoption of healthcare models focused on patient needs, innovative microbial treatments, the implementation of blockchain technology within the medical field, the increased utilization of patient-reported outcomes (PROs), expedited regulatory approval pathways, and enhanced interoperability of health data.Key developments shaping this market during the forecast period encompass the incorporation of digital health platforms, breakthroughs in methods of diagnosis, greater financial commitments to research endeavors, a rise in strategic alliances and cooperative agreements, and the growing prominence of treatment modalities that do not rely on pharmaceuticals.

View the full report here:
https://www.thebusinessresearchcompany.com/report/irritable-bowel-syndrome-ibs-treatment-global-market-report

What Are the Drivers Transforming the Irritable Bowel Syndrome (IBS) Treatment Market?
The escalating incidence of irritable bowel syndrome (IBS) is widely anticipated to stimulate the expansion of the market dedicated to IBS treatments in the forthcoming period. Since IBS constitutes a persistent ailment impacting the large intestine, or colon, its increasing frequency is attributed to several factors, including suboptimal daily routines, detrimental dietary practices, environmental pollution exposure, and elevated psychological stress. Therapies for IBS serve to mitigate both the intensity and recurrence of symptomatic manifestations, consequently enhancing patients' overall well-being and empowering them to achieve superior self-management of their ailment. As an illustration, data from the International Foundation for Gastrointestinal Disorders (IFFGD), a US-based non-profit entity focused on research and education, indicated that in 2023, approximately 5 to 10 percent of the world's population experienced IBS, with estimates suggesting that between 25 and 45 million individuals in the United States alone suffer from this condition; this surge in IBS occurrences, consequently, serves as a powerful engine fueling the growth trajectory of the IBS treatment market.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=11978&type=smp

What Long-Term Trends Will Define the Future of the Irritable Bowel Syndrome (IBS) Treatment Market?
A significant development observed within the irritable bowel syndrome (IBS) market revolves around the rising prominence of novel product introductions. Leading participants in the IBS arena are focusing considerable resources on developing cutting-edge, superior offerings as a means to solidify their market standing. Illustratively, in April 2022, Ardelyx, a biotechnology firm situated in the United States, introduced IBSRELA, representing a pioneering therapy designated specifically for adults afflicted with IBS-C. This formulation uniquely stands as the inaugural and sole available NHE3 inhibitor approved for managing irritable bowel syndrome accompanied by constipation (IBS-C) in adults. Being the first medication from Ardelyx to secure endorsement from the FDA, IBSRELA constitutes the first therapeutic approach employing a novel mechanism for IBS-C to surface in approximately a decade, thereby presenting a substantially important new recourse for alleviating the discomfort associated with abdominal pain, bloating, and constipation characteristic of this debilitating condition.

Which Segments in the Irritable Bowel Syndrome (IBS) Treatment Market Offer the Most Profit Potential?
The irritable bowel syndrome (ibs) treatmentmarket covered in this report is segmented -

1) By Drug Type: Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, Other Drugs
2) By Indication: IBS With Constipation, IBS With Diarrhea, IBS With Alternating Constipation And Diarrhea
3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies
4) By End-Users: Hospitals, Clinics, Homecare Settings

Subsegments:
1) By Lubiprostone: Chronic Idiopathic Constipation Treatment; Irritable Bowel Syndrome with Constipation (IBS-C) Treatment
2) By Linaclotide: IBS-C Treatment; Chronic Idiopathic Constipation Treatment
3) By Eluxadoline: IBS with Diarrhea (IBS-D) Treatment
4) By Rifaximin: IBS-D Treatment; Small Intestinal Bacterial Overgrowth (SIBO) Treatment
5) By Alosetron: Severe IBS-D Treatment for Women
6) By Other Drugs: Prucalopride; Tenapanor; Plecanatide

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=11978&type=smp

Which Firms Dominate the Irritable Bowel Syndrome (IBS) Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the irritable bowel syndrome (IBS) treatment market include Pfizer Inc., Johnson & Johnson Services Inc., AbbVie Inc., Novartis AG, AstraZeneca plc, Abbott Laboratories, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Astellas Pharma Inc., Biogen Inc., Bausch Health Companies Inc., Ironwood Pharmaceuticals Inc., Sebela Pharmaceuticals Inc., Prometheus Laboratories Inc., RedHill Biopharma Ltd., Ardelyx Inc., Cosmo Technologies Ltd., Renexxion Ireland Ltd., 4D Pharma plc, Biora Therapeutics Inc.

Which Regions Offer the Highest Growth Potential in the Irritable Bowel Syndrome (IBS) Treatment Market?
North America was the largest region in the irritable bowel syndrome (IBS) treatment market in 2024. Europe is expected to be the fastest-growing region in the forecast period. The regions covered in the irritable bowel syndrome (IBS) treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=11978

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.